FindTrial
Sign In

Study to compare effect of buprenorphine versus dexmedetomidine given in spinal anaesthesia along with ropivacaine heavy

A prospective randomised control trial comparing the effect of intrathecal buprenorphine versus dexmedetomidine on spinal anaesthesia with hyperbaric ropivacaine - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072852
Enrollment
60
Registered
2024-08-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S720- Fracture of head and neck of femur Health Condition 2: S822- Fracture of shaft of tibia Health Condition 3: K358- Other and unspecified acute appendicitis Health Condition 4: K409- Unilateral inguinal hernia, without obstruction or gangrene

Interventions

Intervention1: Buprenorphine: Single dose of 60microgram intrathecally along with hyperbaric ropivacaine 15mg. Its effects are monitored for 24hrs. Control Intervention1: Dexmedetomidine: Single dose

Sponsors

Vishwanath Amarappa
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients coming for below umbilical surgeries such as appendicectomy, inguinal hernia surgery, fracture of femur or tibia or ankle. Patients belonging to ASA (American society of anaesthesia) grade 1 or 2.

Exclusion criteria

Exclusion criteria: Patients having allergy to the local anaesthetic drugs, coagulation disorders and uncontrolled comorbid conditions.

Design outcomes

Primary

MeasureTime frame
Postoperative of analgesiaTimepoint: 24hrs—

Secondary

MeasureTime frame
Side effects such as nausea, vomitingTimepoint: 24hrs—

Countries

India

Contacts

Public ContactVishwanath Amarappa

Navodaya medical college hospital and research center, Raichur, Karnataka

vishwanath.meti@gmail.com9886777750

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026